Oceania · Regional markets · Stockhead

TrivarX takes key step towards trial of next-gen cancer imaging technology

Published by Stockhead · Australia 11 h ago

Syntro Health will undertake laboratory formulation activities for the Stabl-Im investigational product, with TrivarX (ASX:TRI) targeting first patient enrolment in ... Read More…

Read the full article on Stockhead Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stockhead.com.au)

Also worth reading

Business News (WA)

TrivarX takes key step towards trial of next-gen cancer imaging technology

Share

Also worth reading

Poland fails in bid to call senior Liberals

Chalmers says investors feel good about Australia despite gloom at home

The property crackdown buyers and renters will love

Here are the top 10 ASX 200 shares today

Not lovin’ it: Phillip Island rejects McDonald’s after 1,500 objections

Why Kiwi film director gave up his career to buy a property maintenance franchise